Idiopathic Hypersomnia in the UK: Why Diagnosis and Treatment Are So Hard to Access
The UK has no licensed treatment for idiopathic hypersomnia, and unusually, it once did. Modafinil held a European licence for IH until the EMA concluded the evidence did not outweigh the risks, with the indication formally removed by European Commission decision in January 2011. Every medicine used for IH in the UK is therefore off-label, which gives GPs a reason to decline shared care and commissioners a reason to question funding. Xywav, the only medicine anywhere licensed for IH, is approved in the United States and not available in the UK for this condition. The NHS removes the affordability barrier but replaces it with rationing by time and geography: more than 30,000 people are waiting for sleep studies, sleep medicine is not a standalone specialty, there is no NICE guideline or national commissioning policy for IH, and three ICBs account for over half of all high-cost narcolepsy drug issuance in England. Three practical UK issues matter as much as the prescription: you are legally required to notify the DVLA about excessive sleepiness lasting three months or more, IH will often meet the Equality Act 2010 definition of disability and trigger reasonable adjustments at work, and prescriptions are chargeable in England but free in Scotland, Wales, and Northern Ireland. Narcolepsy UK is the main patient charity covering IH.